Status:
UNKNOWN
Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019
Lead Sponsor:
Fuzhou General Hospital
Conditions:
COVID-19 Pneumonia
Eligibility:
All Genders
18-70 years
Phase:
EARLY_PHASE1
Brief Summary
The outbreak of coronavirus disease 2019 (COVID-19) at the end of 2019 has seen numerous patients experiencing severe acute lung injury (ALI), which developed into severe respiratory distress syndrome...
Detailed Description
In vitro, Mesenchymal stem cells were revealed to inhibit the secretion of inflammatory cytokines by spleen lymphocytes and up-regulate regulatory T cells, thereby inhibiting the secretion of interfer...
Eligibility Criteria
Inclusion
- patients with severe COVID-19 pneumonia
- willing to give informed consent
Exclusion
- patients with mild COVID-19 pneumonia
- liver dysfunction
- concomitant with other active infection
- renal dysfunction
- Heart failure \>grade 2
- pregnant
- history of COPD
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04371601
Start Date
March 1 2020
End Date
December 31 2022
Last Update
May 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fuzhou General Hospital
Fuzhou, Fujian, China, 350025